Action 18H PREVECEUTICAL MEDICAL INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues PreveCeutical Medical Inc. Deutsche Boerse AG

Actions

18H

CA74141E1043

Marché Fermé - Deutsche Boerse AG
Autres places de cotation
 15:45:29 03/05/2024 		Varia. 5j. Varia. 1 janv.
0,019 EUR +80,95% Graphique intraday de PreveCeutical Medical Inc. +26,67% +35,71%
2023 PreveCeutical Medical Inc. lance la préparation d'une étude préclinique pour ses maladies et obtient la preuve de concept de son programme de thérapie génique double CI
2023 PreveCeutical Medical Inc. annonce ses résultats pour le troisième trimestre et les neuf mois terminés le 30 septembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
PreveCeutical Announces Management Cease Trade Order
PreveCeutical Medical Inc. announced that it expects to receive CAD 0.25 million in funding
PreveCeutical Medical Inc. Initiates Preparation of Preclinical Study for Its Diseases & Obtains Proof-Of-Concept Dual Gene Therapy Program
PreveCeutical Medical Prepares For Proof of Concept Preclinical Study For Diabetes, Obesity Dual Gene Therapy Program
PreveCeutical Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
PreveCeutical & Endosane Announce Update on Intranasal CBD Application
PreveCeutical Medical Inc. and Endosane Pharmaceuticals GmbH Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD and Pharmacologically Relevant Doses Following Intranasal CBD Application
PreveCeutical Medical Inc. Showcases Dynamic Evolution in AI Strategy
PreveCeutical Medical : Showcases Dynamic Evolution in AI Strategy
PreveCeutical Engages New to the Street for Production and Broadcasting Services
PreveCeutical Medical : Engages New to the Street for Production & Broadcasting Services
PreveCeutical Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
PrevCeutical Medical Provides Update
PreveCeutical Medical Inc. Files Cyclic Peptides and Uses Thereof in EU and Australia
PreveCeutical Medical : Files Cyclic Peptides And Uses Thereof in the EU and Australia
PreveCeutical Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use and Cyclic Peptides and Uses Thereof
PreveCeutical Medical Inc. Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof
PreveCeutical Medical : Files Two Family Patents of Sol-Gel Cannabinoid Formulation And Antiviral Use & Cyclic Peptides And Uses Thereof
Preveceutical Medical Inc. Furthering the Progress of Its Patent Family Directed to Sol-Gel
PreveCeutical Medical : Sol-Gel and Uses thereof Patent Update
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PREV
  4. Action 18H
  5. Actualités PreveCeutical Medical Inc.
  6. Autres langues